Related Experiment Video

Updated: Jun 6, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Bcl-2 targeted-therapy for the treatment of head and neck squamous cell carcinoma

Lucas V dos Santos1, André L Carvalho

  • 1Medical Oncology Department, Barretos Cancer Hospital, Barretos -SP, 14784-400, Brazil.

Recent Patents on Anti-Cancer Drug Discovery
|November 30, 2010
PubMed

Insights

Targeting Bcl-2 family proteins, crucial for apoptosis regulation, offers a promising strategy to enhance head and neck cancer treatment efficacy. New drugs and patents focus on inhibiting these proteins to improve patient survival rates.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Head and neck cancer survival rates have stagnated despite treatment advancements.
  • Bcl-2 family proteins are key regulators of apoptosis, a process vital in cancer development.
  • Dysregulation of apoptosis contributes to head and neck cancer progression.

Purpose of the Study:

  • To elucidate the role of Bcl-2 family proteins in head and neck cancer pathogenesis.
  • To review novel targeted-therapy strategies for Bcl-2 and related proteins.
  • To assess the potential of these therapies to improve systemic treatment efficacy.

Main Methods:

  • Literature review of Bcl-2 family proteins in head and neck cancer.
  • Analysis of recent drug development and patent landscape for Bcl-2 inhibitors.
  • Discussion of targeted therapy mechanisms and potential clinical applications.

Main Results:

  • Bcl-2 family proteins are implicated in resistance to apoptosis in head and neck cancers.
  • Emerging small molecules and antibodies target specific Bcl-2 family members.
  • Patents indicate significant investment in developing novel inhibitors.

Conclusions:

  • Targeted inhibition of Bcl-2 family proteins represents a promising therapeutic avenue for head and neck cancer.
  • New drugs targeting Bcl-2 could overcome treatment resistance and improve patient outcomes.
  • Further research and clinical trials are warranted to validate these targeted therapies.

More Related Videos

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Translationally-Relevant Tumor Resection Model for Murine Preclinical Models of Oral Squamous Cell Carcinoma07:59

Translationally-Relevant Tumor Resection Model for Murine Preclinical Models of Oral Squamous Cell Carcinoma

Published on: April 3, 2026

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...